Publications

Poster Presentations

Lemech, Charlotte R. et al., Clinical validation of an orally-delivered, systemically activated TLR7 agonist to boost host immune response to chronic viral diseases, including hepatitis B virus, Presented at the American Association for the Study of Liver Disease Annual Meeting (The Liver Meeting, 2023). [Poster]

Lemech, Charlotte R. et al., Activation of Innate and Adaptive Immune Response with a Clinical Stage TLR7 Agonist Prodrug PRTX007, Presented at the American Association of Cancer Research (AACR) Annual Meeting, 2023. [Poster]

Lemech, Charlotte R. et al., PRTX007, an Optimized TLR7 Agonist for Systemic Immunotherapy of Cancers: Interim Analysis of Phase I Study in Healthy Volunteers, Presented at the American Association of Cancer Research (AACR) Annual Meeting, 2022. [Poster]

Appleman, James R. et al. Antiviral Activity of the Clinical Stage TLR7 Agonist Prodrug PRTX007 in a Murine Respiratory Syncytial Virus Animal Model, Presented at the 35th International Conference on Antiviral Research (ISAR/ICAR), 2022. [Poster]

Appleman, James R. et al., PRTX007, a TLR7 Agonist, Demonstrates Broad-Spectrum Antiviral Activity and Is Appropriate for Pandemic Preparedness, Presented at the 35th International Conference on Antiviral Research (ISAR/ICAR), 2022. [Poster]

Lemech, Charlotte R. et al., Interim Analysis of a Phase 1 Study of PRTX007: Safety, PK and PD Response, Presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI), 2022. [Poster]

Appleman, James R. et al., Selection of a Novel Toll-Like Receptor 7 (TLR7) Agonist PRX034 for Immunotherapy of Cancer, Presented at the American Association of Cancer Research (AACR) Annual Meeting, 2020. [Poster]

Appleman, James R. et al., Pharmacodynamic Response In Vitro and In Vivo of Novel Orally Administered Toll-Like Receptor 7 Agonists for Systemic Immunotherapy of Cancer, Presented at the 34th Annual Meeting and Pre-conference Programs of the Society for Immunotherapy of Cancer (SITC), 2019. [Poster]

Appleman, James R. et al., Discovery of a Series of Novel Toll-Like Receptor 7 Agonists for Systemic Immunotherapy of Cancer, Presented at the American Association of Cancer Research (AACR) Annual Meeting, 2019. [Poster]

Conference Presentations

PRTX007, A Novel Orally Administered TLR7 Agonist Prodrug for the Treatment of Cancer, Sting and TLR-Targeting Therapeutics Summit, May 25-27, 2021. [Slides]

Developing TLR7 agonists to treat chronic and acute infections, World Vaccine and Immunotherapy Congress West Coast & World Antiviral Congress San Diego, CA 2021 Nov 30 – Dec 2, 2021. [Slides]

Driving Innate Immunity via TLR7 Agonism (PRTX007, a Novel Orally Administered TLR7 Agonist Prodrug From Primmune Therapeutics for the Treatment of Cancer), STING & TLR-Targeting Therapies Summit May 9-11, 2023. [Slides]